|Elimination half-life||41-59 min|
|Chemical and physical data|
|Molar mass||427.454 g/mol g·mol−1|
|3D model (JSmol)|
|(what is this?)|
Cefoxitin is a second-generation cephamycin antibiotic developed by Merck & Co., Inc. from Cephamycin C in the year following its discovery, 1972. It was synthesized in order to create an antibiotic with a broader spectrum. It is often grouped with the second-generation cephalosporins. Cefoxitin requires a prescription and as of 2010 is sold under the brand name Mefoxin by Bioniche Pharma, LLC. The generic version of Mefoxin is known as cefoxitin sodium.
- 1 History and discovery
- 2 Mechanism
- 3 Microbiological resistance
- 4 Spectrum of bacterial susceptibility
- 5 Replacement and substitution
- 6 Uses in medicine
- 7 Side effects
- 8 Notable drug interactions
- 9 Pharmacodynamic and pharmacokinetic data
- 10 References
History and discovery
Groups of researchers at Merck and Lilly discovered Cephamycin C while looking at penicillin-producing bacteria. This followed their discovery of erythromycin, another antibiotic. Cephamycin C was the first cephem discovered but while it was highly resistant to a lot of beta-lactamases, as is its derivative cefoxitin, it was almost only effective against Gram negative bacteria. The scientists used chemistry to modify the compound, which gives cefoxitin the title of semi-synthetic since a biological product is altered to artificially synthesize it. This new modification broadened its spectrum to include Gram positive bacteria. More than 300 modifications were made to it and tested on the cephalosporin base with methoxy groups at the 7-alpha position. Yet cefoxitin was the compound that was successful in keeping its previous effectiveness against Gram negative bacteria, developed effectiveness against Gram positive bacteria, and was resistant to breakdown by beta-lactamase.
Cefoxitin, and the cephamycin family as a whole, served as a branching point and impulsed the discovery of more classes of beta-lactams. This is in part due to their primary and early discovery in the broths studied.
Cefoxitin is a beta-lactam antibiotic which binds penicillin binding proteins, or transpeptidases. By binding to PBPs, cefoxitin prevents the PBPs from forming the cross-linkages between the peptidoglycan layers that make up the bacterial cell wall, thereby interfering with cell wall synthesis. It is a strong beta-lactamase inducer, as are certain other antibiotics (such as imipenem). However, cefoxitin is a better substrate than imipenem for beta-lactamases.
In the presence of cefoxitin, bacteria that make beta-lactamases will increase their production and secretion to cleave the beta lactam ring. As a cephamycin, cefoxitin is highly resistant to hydrolysis by some beta-lactamases, in part due to the presence of the 7-alpha-methoxy functional group (see skeletal formula above).
Another more efficient form of resistance to cefoxitin is provided by the mecA gene in bacteria. This gene codes for an alternative penicillin binding protein, PBP2a. This PBP has a lower binding affinity for penicillin-based antibiotics such as cefoxitin and will continue to cross-link the peptidoglycan layers of the cell wall even in the presence of the beta-lactam antibiotics. MRSA, or methicillin-resistant Staphylococcus aureus is a strain that has acquired resistance to cefoxitin via this gene. For the purposes of detecting bacterial strains with the mecC gene, which like mecA codes for a different PBP, cefoxitin is more reliable than oxacillin because mecC does not correlate as strongly with oxacillin resistance.
Spectrum of bacterial susceptibility
Cefoxitin's spectrum of in vitro antimicrobial activity includes a broad range of gram-negative and gram-positive bacteria, including anaerobes. It is inactive against most strains of Pseudomonas aeruginosa and many strains of Enterobacter cloacae. Staphylococci that are resistant to methicillin and oxacillin should also be considered clinically resistant to cefoxitin even if they test susceptible by in vitro methods.
Major bacterial strains susceptible to cefoxitin include:
- methicillin-susceptible Staphylococcus aureus
- Streptococcus sp.
- E. coli
- Salmonella sp.
- Proteus vulgaris
- Flavobacterium sp.
- Klebsiella sp.
Major bacteria resistant to cefoxitin include:
- methicillin-resistant Staphylococcus aureus
- Listeria monocytogenes
- Enterobacter sp.
- Bacteroides sp.
Replacement and substitution
In a 2005 study, Fernandes et al. determined that cefoxitin serves as an appropriate replacement for methicillin in determining if some bacteria display methicillin resistance. Likewise, Funsun et al. found in a 2009 study that cefoxitin disk assays correctly identified all 60 mecA-positive Staphylococcus aureus, or MRSA isolates, to be resistant to cefoxitin.
Due, in part, to the unavailability of methicillin in the United States, cefoxitin has replaced methicillin for disk diffusion tests, which determine the sensitivity of a bacterial specimen to a given antibiotic. Cefoxitin also yields more accurate results for disk diffusion tests. Interpretive criteria for determining susceptibility to cefoxitin via disk diffusion are greater than or equal to 22mm resulting in a "susceptible" result for Staphylococcus aureus and greater than or equal to 25mm for coagulase-negative staphylococci to be considered susceptible.
The following are susceptibility data for several medically significant microorganisms, measured by minimum inhibitory concentration, which is an alternative, liquid medium test for susceptibility.
- Escherichia coli: 0.2 μg/ml – 64 μg/ml
- Haemophilus influenzae: 0.5 μg/ml – 12.5 μg/ml
- Streptococcus pneumoniae: 0.2 μg/ml – 1 μg/ml
Uses in medicine
Cefoxitin is sold in three major IV doses, 1g, 2g, and 10g. It is usually given to adults every six to eight hours in 1g or 2g doses. Cefoxitin may interfere with tests detecting urine glucose and result in a false positive. As with any antibiotic, it should not be given to patients who are allergic to it.
- Skin infections, primarily due to Staphylococcus
- Urinary tract infections
- Ear infections
- Bacterial pneumonia
- Bone and joint infections
- Abdominal infections and abscesses
- Perineum injuries
- Pelvic inflammatory disease
- Infections caused by susceptible bacteria mentioned earlier
Cefoxitin has many other uses; it may be given prior to surgery to prevent the development of surgical wound infections, and when used in third and fourth degree perineal injuries in women after giving vaginal birth, cefoxitin decreases infection rate at two and six weeks. However, the earlier and more times a child is exposed to cefoxitin, as with early and multiple exposure to many antibiotics, the greater the likelihood of developing inflammatory bowel disease later in life. This may be due in part to a decreased variety of microorganisms in the digestive system.
It is also used to treat pelvic inflammatory disease, because it is a broad spectrum antibiotic. For outpatient treatment, oral antibiotics or those with less frequent dosing may be prescribed. As an effective alternative to penicilin and spectinomycin, and replacement for methicillin, cefoxitin is used to treat gonorrhea in both men and women with few side effects.
- local tenderness or pain at the site of injection
- skin color change, mild diarrhea
- mild nausea
- loss of appetite
- vaginal discharge and itching
- swelling of feet or legs.
While cefoxitin has not been associated with alcohol incompatibility like other members of the second generation cephalosporins class, it has been with a higher risk of coagulopathy, a bleeding disorder.
This is not a comprehensive list and not intended to provide medical advice. If any of the previous side effects are severe, or if an allergic reaction takes place immediately contact your doctor.
Notable drug interactions
A contraindication means that the drug in question should not be used under particular circumstances. For cefoxitin, this includes patients who are hypersensitive to cephalosporin antibiotics.
Patients with colitis, kidney disease, or liver disease are also advised not to take cefoxitin. However, some drug databases will considers the diseases means for caution rather than contraindications.
Major or Severe
Aside from the above-mentioned contraindications and diseases which require monitoring by a doctor, the live cholera and live typhoid vaccines are known to have a severe interaction with cefoxitin.
Individuals on a low sodium diet, undergoing dialysis, or who have experienced seizures, particularly following antibiotic therapy, should also consult their physician prior to taking cefoxitin.
Only take additional antibiotics, anticoagulants and blood thinners under doctor supervision. Cefoxitin may decrease the effectiveness of hormonal birth control. This increases the risk for pregnancy and a medical consult will help determine whether backup birth control methods should be used.
Minor drug interactions do not usually require a change in treatment. Your doctor may monitor specific events, such as bleeding, while taking cefoxitin. Two such minor interactions occur between cefoxitin and heparin as well as genistein.
Pharmacodynamic and pharmacokinetic data
One such study was by the Hôpitaux de Paris in collaboration with the French Ministry of Health. However, while the clinical trials were completed in 2015, no study data have been published. The expected results from using cefoxitin over carbapenems, another type of antibiotic with a wider bacterial spectrum, included effective treatment of E. coli produce extended spectrum beta-lactamase, less selective pressure on the GI tract which better maintains balanced flora, and a lower treatment cost.
This followed a 2012 French study on the same E. coli strain with CTX-M-15 extended release beta-lactamase. Lepeule et al. determined that in mice, the ideal pharmacodynamic target of fT>MIC=33%, where MIC is the minimum inhibitory concentration, was obtained with 200 mg/kg every four hours. The fT>MIC (%) was increased by 11% when the administration frequency was increased from every four hours to every three hours. This implied that increasing the frequency might yield similar results in humans. The study also found no significant difference between the effectiveness of carbapenems and cefoxitin and suggested that cefoxitin can be used as an alternative treatment for CTX-M producing E. coli to carbapenems such as imipenem and ertapenem.
- Gootz, T D (1990-01-01). "Discovery and development of new antimicrobial agents". Clinical Microbiology Reviews. 3 (1): 13–31. doi:10.1128/cmr.3.1.13. ISSN 0893-8512. PMC 358138. PMID 2404566.
- Levy, Stuart B. (2013-11-11). The Antibiotic Paradox: How Miracle Drugs Are Destroying the Miracle. Springer. ISBN 9781489960429.
- "Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations". www.accessdata.fda.gov. Retrieved 2017-05-04.
- "Supplement Approval" (PDF). Food and Drug Administration. Department of Health and Human Services.
- Dougherty, Thomas J.; Pucci, Michael J. (2011-12-21). Antibiotic Discovery and Development. Springer Science & Business Media. ISBN 9781461413998.
- Sneader, Walter (2005-06-23). Drug Discovery: A History. John Wiley & Sons. ISBN 9780471899792.
- Phillips I, Shannon K (1993). "Importance of beta-lactamase induction". European Journal of Clinical Microbiology and Infectious Diseases. 12 Suppl 1: S19–26. doi:10.1007/bf02389873. PMID 8477758.
- Moellering, Robert C.; Dray, Marie; Kunz, Lawrence J. (1974-09-01). "Susceptibility of Clinical Isolates of Bacteria to Cefoxitin and Cephalothin". Antimicrobial Agents and Chemotherapy. 6 (3): 320–323. doi:10.1128/aac.6.3.320. ISSN 0066-4804. PMC 444644. PMID 15830480.
- Shaikh, Sibhghatulla; Fatima, Jamale; Shakil, Shazi; Rizvi, Syed Mohd. Danish; Kamal, Mohammad Amjad (2015-01-01). "Antibiotic resistance and extended spectrum beta-lactamases: Types, epidemiology and treatment". Saudi Journal of Biological Sciences. Special issue: Biological Aspects of Global Health Issues. 22 (1): 90–101. doi:10.1016/j.sjbs.2014.08.002. PMC 4281622. PMID 25561890.
- Onishi, H. Russell; Daoust, Donald R.; Zimmerman, Sheldon B.; Hendlin, David; Stapley, Edward O. (1974-01-01). "Cefoxitin, a Semisynthetic Cephamycin Antibiotic: Resistance to Beta-Lactamase Inactivation". Antimicrobial Agents and Chemotherapy. 5 (1): 38–48. doi:10.1128/aac.5.1.38. ISSN 0066-4804. PMC 428916. PMID 4599124.
- Fonze, Eveline (January 15, 2002). "Crystal Structures of the Bacillus licheniformis BS3 Class A β-Lactamase and of the Acyl−Enzyme Adduct Formed with Cefoxitin". Biochemistry. 41 (6): 1877–1885. doi:10.1021/bi015789k.
- Paterson, Gavin K.; Harrison, Ewan M.; Holmes, Mark A. (2017-05-04). "The emergence of mecC methicillin-resistant Staphylococcus aureus". Trends in Microbiology. 22 (1): 42–47. doi:10.1016/j.tim.2013.11.003. ISSN 0966-842X. PMC 3989053. PMID 24331435.
- Skov, Robert; Larsen, Anders Rhod; Kearns, Angela; Holmes, Mark; Teale, Christopher; Edwards, Giles; Hill, Robert (2014-01-01). "Phenotypic detection of mecC-MRSA: cefoxitin is more reliable than oxacillin". The Journal of Antimicrobial Chemotherapy. 69 (1): 133–135. doi:10.1093/jac/dkt341. ISSN 1460-2091. PMID 24038776.
- Mefoxin Official FDA information at Drugs.com
- Fernandes, Clarence J.; Fernandes, Lorna A.; Collignon, Peter (2005-04-01). "Cefoxitin resistance as a surrogate marker for the detection of methicillin-resistant Staphylococcus aureus". Journal of Antimicrobial Chemotherapy. 55 (4): 506–510. doi:10.1093/jac/dki052. ISSN 0305-7453. PMID 15743899.
- Akcam, Fusun Zeynep; Tinaz, Gulgun Bosgelmez; Kaya, Onur; Tigli, Arzu; Ture, Ebru; Hosoglu, Salih (2009-01-01). "Evaluation of methicillin resistance by cefoxitin disk diffusion and PBP2a latex agglutination test in mecA-positive Staphylococcus aureus, and comparison of mecA with femA, femB, femX positivities". Microbiological Research. 164 (4): 400–403. doi:10.1016/j.micres.2007.02.012. PMID 17481872.
- "Laboratory Testing for MRSA". CDC.gov. CDC. Retrieved 9 May 2017.
- "Mefoxin Drug Information, Indications & Other Medicaments". www.catalog.md. Retrieved 2017-04-28.
- Cunha, John. "Common Side Effects of Mefoxin (Cefoxitin) Drug Center - RxList". RxList. Retrieved 2017-05-02.
- "Mefoxin tablet :: Generic, Side effects, Interchangeable drugs, etc." edudrugs.com. Retrieved 2017-04-28.
- "Mefoxin Indication, Action of Mefoxin, Interactions." edudrugs.com. Retrieved 2017-04-28.
- "Cefoxitin Mefoxitin 1g". Marzan Pharma Corporation. Retrieved 2017-04-28.
- "Méfoxin generic. Price of méfoxin. Uses, Indications and Description". ndrugs. Retrieved 2017-04-28.
- "Cefoxitin (By injection) - National Library of Medicine - PubMed Health". U.S. National Library of Medicine. April 1, 2017 Health. Retrieved 2017-04-28. Check date values in:
- Bratzler, Dale W.; Houck, Peter M. (2005-04-01). "Antimicrobial prophylaxis for surgery: An advisory statement from the National Surgical Infection Prevention Project". The American Journal of Surgery. 189 (4): 395–404. doi:10.1016/j.amjsurg.2005.01.015. PMID 15820449.
- Buppasiri, Pranom; Lumbiganon, Pisake; Thinkhamrop, Jadsada; Thinkhamrop, Bandit (2014-10-07). "Antibiotic prophylaxis for third- and fourth-degree perineal tear during vaginal birth". The Cochrane Database of Systematic Reviews (10): CD005125. doi:10.1002/14651858.CD005125.pub4. ISSN 1469-493X. PMID 25289960.
- Kronman, Matthew P.; Zaoutis, Theoklis E.; Haynes, Kevin; Feng, Rui; Coffin, Susan E. (2017-04-28). "Antibiotic Exposure and IBD Development Among Children: A Population-Based Cohort Study". Pediatrics. 130 (4): e794–e803. doi:10.1542/peds.2011-3886. ISSN 0031-4005. PMC 4074626. PMID 23008454.
- Sexually transmitted diseases :treatment guidelines. Atlanta, GA: U.S. Department of Health and Human Services. hdl:2027/uiug.30112023431809.
- Survey of research on sexually transmitted diseases /. Atlanta, Ga. :. 1985-01-01. hdl:2027/umn.31951000325661b.
- "Méfoxin Side effects, Contraindications". ndrugs. Retrieved 2017-05-02.
- "Mefoxin (Cefoxitin) Drug Information: Overdosage and Contraindications - Prescribing Information at RxList". RxList. Retrieved 2017-05-29.
- "Mefoxin (Cefoxitin) - Drug Interactions, Contraindications, Other Rx Info". www.druglib.com. Retrieved 2017-05-29.
- "Contraindications for Cefoxitin Vial". WebMD. Retrieved 2017-05-29.
- "cefoxitin Contraindications and Cautions - Epocrates Online". online.epocrates.com. Retrieved 2017-05-29.
- "Cefoxitin Drug Interactions - Drugs.com". Drugs.com. Retrieved 2017-05-29.
- "Cefoxitin Vial Interactions with Other Medication". WebMD. Retrieved 2017-05-29.
- "Cefoxitin Drug Interactions - Drugs.com". Drugs.com. Retrieved 2017-05-29.
- "Camrese and cefoxitin Drug Interactions - Drugs.com". Drugs.com. Retrieved 2017-05-29.
- "Cefoxitin and heparin Drug Interactions - Drugs.com". Drugs.com. Retrieved 2017-05-29.
- "Cefoxitin and cholecalciferol / genistein / zinc chelazome Drug Interactions - Drugs.com". Drugs.com. Retrieved 2017-05-29.
- "Efficacy and Pharmacokinetic/Pharmacodynamic Parameters of Cefoxitin in Women With Acute Pyelonephritis Without Severity Symptoms Due to Extended-spectrum β-lactamase Producing Escherichia Coli. - ICH GCP - Clinical Trials Registry". ichgcp.net. Retrieved 2017-05-29.
- "Efficacy and Pharmacokinetic/Pharmacodynamic Parameters of Cefoxitin in Women With Acute Pyelonephritis Without Severity Symptoms Due to Extended-spectrum β-lactamase Producing Escherichia Coli - Full Text View - ClinicalTrials.gov". clinicaltrials.gov. Retrieved 2017-05-29.
- Lepeule, Raphaël; Ruppé, Etienne; Le, Patrick; Massias, Laurent; Chau, Françoise; Nucci, Amandine; Lefort, Agnès; Fantin, Bruno (2012-03-01). "Cefoxitin as an Alternative to Carbapenems in a Murine Model of Urinary Tract Infection Due to Escherichia coli Harboring CTX-M-15-Type Extended-Spectrum β-Lactamase". Antimicrobial Agents and Chemotherapy. 56 (3): 1376–1381. doi:10.1128/AAC.06233-11. ISSN 0066-4804. PMC 3294923. PMID 22214774.
- Lepeule, Raphaël; Ruppé, Etienne; Le, Patrick; Massias, Laurent; Chau, Françoise; Nucci, Amandine; Lefort, Agnès; Fantin, Bruno. "Cefoxitin as an Alternative to Carbapenems in a Murine Model of Urinary Tract Infection Due to Escherichia coli Harboring CTX-M-15-Type Extended-Spectrum β-Lactamase". Retrieved 2017-05-29.